Eli Lilly

Page 2 of 7

Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve.
Commentary

The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up

By
March 4, 2025
Eli Lilly's headquarters sits behind a gate with the US flag raised
Finance

Eli Lilly to spend $27 billion to bolster U.S. drug manufacturing as Trump tariffs loom

By Madison Muller and Bloomberg
February 26, 2025
Semaglutide medications Wegovy and Ozempic are pictured
Health

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

By Bloomberg, Madison Muller, Ike Swetlitz and Naomi Kresge
February 21, 2025
United States President Donald J. Trump speaks at the Friends of Ireland luncheon hosted by United States Speaker of the House of Representatives Paul Ryan, Republican of Wisconsin, at the United States Capitol March 15, 2018 in Washington, DC.
Finance

Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead

By
February 19, 2025
A woman injects herself with medication.
Health

Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’

By
February 11, 2025
A young woman undergoes a brain scan.

Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug

By
February 6, 2025
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript

Eli Lilly (LLY) Q4 2024 Earnings Call Transcript

By
February 6, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

By
February 5, 2025
A person stands on a scale.
Health

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

By
February 3, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health

Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next

By
January 29, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
Arianna Huffington
Newsletters

Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly

By Alexa Mikhail and Nina Ajemian
January 9, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
Health

Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict

By
December 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health

Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints

By Ryan Hogg and AFP
December 20, 2024

Most Popular